New Stem Cell Lines Open to Research
The National Institutes of Health said Wednesday that it had approved 13 new human embryonic stem cell lines for use by federally financed researchers, with another 96 lines under review.
The action followed President Obama’s decision in March to expand the number of such cell lines beyond those available under a policy set by President George W. Bush, which permitted research to begin only with lines already available on Aug. 9, 2001.
Since that date, biomedical researchers supported by the N.I.H. have had to raise private money to derive the cells, which are obtained from the fertilized embryos left over from in vitro fertility clinics.
With federal money banned from being used in any part of the work on the derived lines, researchers had to divide their laboratories and go to extreme lengths to separate research materials based on the financing source.
“You can imagine what it meant not to be able to carry a pipette from one room to another,” said Ali H. Brivanlou, a researcher at Rockefeller University. “They even had to repaint the walls to ensure no contamination by federal funds.”
Two of the newly approved 13 lines were derived by Dr. Brivanlou with private financing. The rest were prepared by Dr. George Daley of Children’s Hospital, Boston.
Dr. Daley said that private financing had been drying up and that he was eager to start research on the now-approved cell lines with the help of his federal grant money.
The director of the health agency, Dr. Francis S. Collins, said he believed most researchers would be satisfied with the outcome, even though they were still barred from deriving the cells themselves. “I’m not sure everyone is interested in deriving their own cell lines as long as they can get lines from others,” Dr. Collins said.
Researchers’ interest in human embryonic stem cells has abated since the discovery in 2007 by the Japanese biologist Dr. Shinya Yamanaka that the mature cells of the body can be reprogrammed to the embryonic state.
These induced embryonic cells are highly similar to the real thing but may not be exactly the same. One reason is that the mature cell may perceive the forced walk-back to embryonic state as unauthorized and switch on its anticancer defenses.
Because the reprogrammed cells and those derived from leftover human embryos may not be identical, researchers need to work with both kinds, Dr. Collins said.
The National Institutes of Health said Wednesday that it had approved 13 new human embryonic stem cell lines for use by federally financed researchers, with another 96 lines under review.
The action followed President Obama’s decision in March to expand the number of such cell lines beyond those available under a policy set by President George W. Bush, which permitted research to begin only with lines already available on Aug. 9, 2001.
Since that date, biomedical researchers supported by the N.I.H. have had to raise private money to derive the cells, which are obtained from the fertilized embryos left over from in vitro fertility clinics.
With federal money banned from being used in any part of the work on the derived lines, researchers had to divide their laboratories and go to extreme lengths to separate research materials based on the financing source.
“You can imagine what it meant not to be able to carry a pipette from one room to another,” said Ali H. Brivanlou, a researcher at Rockefeller University. “They even had to repaint the walls to ensure no contamination by federal funds.”
Two of the newly approved 13 lines were derived by Dr. Brivanlou with private financing. The rest were prepared by Dr. George Daley of Children’s Hospital, Boston.
Dr. Daley said that private financing had been drying up and that he was eager to start research on the now-approved cell lines with the help of his federal grant money.
The director of the health agency, Dr. Francis S. Collins, said he believed most researchers would be satisfied with the outcome, even though they were still barred from deriving the cells themselves. “I’m not sure everyone is interested in deriving their own cell lines as long as they can get lines from others,” Dr. Collins said.
Researchers’ interest in human embryonic stem cells has abated since the discovery in 2007 by the Japanese biologist Dr. Shinya Yamanaka that the mature cells of the body can be reprogrammed to the embryonic state.
These induced embryonic cells are highly similar to the real thing but may not be exactly the same. One reason is that the mature cell may perceive the forced walk-back to embryonic state as unauthorized and switch on its anticancer defenses.
Because the reprogrammed cells and those derived from leftover human embryos may not be identical, researchers need to work with both kinds, Dr. Collins said.
Source: New York Times
« Back to Health News
Related News
-
Researchers produce cells they say are identical to embryonic stem ... Dec 2, 2009 @ 11:25 AM
Two groups of Chinese researchers have performed an unprecedented feat, it was announced today, by inducing cells from connective tissue in mice to revert back to their embryonic state and producing living mice from them.
-
NIH authorizes use of first human embryonic stem cells under new policy Dec 2, 2009 @ 11:25 AM
The Obama administration on Wednesday approved the first human embryonic stem cells for experiments by federally funded scientists under a new policy designed to dramatically expand government support for one of the most promising but also most contentious fields of biomedical research.
-
Researchers find prostate cancer stem cell Dec 2, 2009 @ 11:25 AM
WASHINGTON (Reuters) - Researchers have found a stem cell, a kind of master cell, that may cause at least some types of prostate cancer.
-
Study confirms limits on stem cell research Dec 2, 2009 @ 11:25 AM
Scientists have long complained that the Bush administration's stem cell funding policy restricted their research to only a handful of human embryonic stem cell lines. A study published Friday in Nature Biotechnology confirms that the majority of lab experiments over the last decade has indeed focused on two or three cell lines -- the result of choices made by both President George W. Bush and the scientists themselves.Researchers from Stanford University, the Mayo Clinic and the University of Michigan analyzed all 1,217 requests for stem cell lines that were made to the National Stem Cell Bank between 1999 and 2008. What they found was "far less diversity of materials than most believe," they wrote. Though the Bush administration said the bank maintained 21 cell lines eligible for funding from the National Institutes of Health, three of those lines have never been available to researchers, and a fourth line just became usable this year, the researchers said.Of the remaining 17 cell lines, more than three-quarters of all requests from scientists involved just two. The H1 line accounted for 39% of the orders, and the H9 line made up an additional 38%, according to records from the stem cell bank. The only other line that has been requested more than 100 times is H7. Nine of the lines haven't even made it into the double digits. It's not clear if only those three lines were easy to work with, or if they were favored for other reasons.The researchers also examined requests for human embryonic stem cell lines developed and maintained by the Harvard Stem Cell Institute. Harvard offers 28 cell lines, though the researchers focused on the 17 that have been available since 2004. (The others were too new to have been requested very often, they reasoned.) None of the Harvard lines could be used in NIH-funded experiments until the Obama administration's more expansive funding policy took effect last month. There was considerably more diversity in Harvard's 946 shipments, according to the study. The two most popular cell lines accounted for only 25% of requests. The researchers also scanned 534 stem cell studies published in peer-reviewed journals between 1999 and 2008. The H9 cell line appeared in 83% of studies, while the H1 line was in 61% and H7 was in 24%. Less than 36% of the publications included any of the other NIH lines.The Harvard lines showed up in fewer than 3% of the studies, according to the analysis. The researchers speculated that scientists using federal funds might have been more conservative about their experiments and thus tended to cluster around the most popular NIH-approved lines. The pattern might also reflect a "first-mover advantage," because laboratories seeking to replicate previous experiments would strive to use the same materials."The lasting legacy of Bush-era policies," the researchers concluded, is a human embryonic stem cell field "that relies very heavily on a small number of well-used but less than ideal cell lines."karen.kaplan@latimes.com
-
Some stem cell lines are more equal than others Dec 2, 2009 @ 11:25 AM
Scientists have long complained that the Bush administration’s stem cell funding policy restricted their research to only a handful of human embryonic stem cell lines. That was an understatement, according to a study published today in Nature Biotechnology.
